Vorsetuzumab mafodotin

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1165741-01-4

Anti-Human CD70 Recombinant Antibody
SGN-75

Vorsetuzumab mafodotin (SGN-75) 是一种基于 Auristatin 的抗CD70抗体药物偶联物 (ADC) Vorsetuzumab mafodotin 由人源化单克隆抗体 Vorsetuzumab 和 ADC 细胞毒素 MMAF 组成，具有抗肿瘤活性。

生物活性

Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and anADC cytotoxinMMAF. Vorsetuzumab mafodotin has antineoplastic activity^[1].

体外研究
(In Vitro)

Vorsetuzumab mafodotin (SGN-75; 0.01-10000 ng/mL; for 96 h) induces dose-dependent cytotoxicity that is specific with an IC₅₀of 29 ng/mL^[1].

Cell Cytotoxicity Assay^[1]

Cell Line:	SK-OV-3 cells
Concentration:	0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL
Incubation Time:	96 h
Result:	Induced dose-dependent cytotoxicity.

体内研究
(In Vivo)

Vorsetuzumab mafodotin (SGN-75; 3 mg/kg; four intraperitoneal injections at 4-day interval) significantly reduces median tumour volumes and delays tumour growth^[1].

Animal Model:	Nude (nu/nu) female mice injected with MiaPaCa-2/CD70 tumour pieces^[1]
Dosage:	3 mg/kg
Administration:	Intraperitoneal injection; every 4 days; for a total of four doses
Result:	Significantly reduced median tumour volumes and delayed tumour growth.

分子量

150 (kDa)

CAS 号

1165741-01-4

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.